Rongrong Luo - Publications

A Novel IgG-IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules.

Journal: Genomics, proteomics & bioinformatics

Published: March 29, 2024

High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer.

Journal: Molecular & cellular proteomics : MCP

Published: August 11, 2023

Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.

Journal: Cancer

Published: July 03, 2023

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.

Journal: Molecular & cellular proteomics : MCP

Published: January 28, 2023

High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: September 04, 2022

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.

Journal: Journal of translational medicine

Published: January 11, 2022

Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays.

Journal: Cancer immunology, immunotherapy : CII

Published: November 21, 2021

The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis.

Journal: Future oncology (London, England)

Published: November 16, 2021

High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.

Journal: Cancer science

Published: July 07, 2021

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.

Journal: Cancer immunology, immunotherapy : CII

Published: May 18, 2021

Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.

Journal: American journal of cancer research

Published: August 01, 2020

CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK.

Journal: Current cancer drug targets

Published: May 26, 2018